ES2380621T3 - Anticuerpos monoclonales humanos contra CD20 - Google Patents

Info

Publication number

ES2380621T3

ES2380621T3 ES03809145T ES03809145T ES2380621T3 ES 2380621 T3 ES2380621 T3 ES 2380621T3 ES 03809145 T ES03809145 T ES 03809145T ES 03809145 T ES03809145 T ES 03809145T ES 2380621 T3 ES2380621 T3 ES 2380621T3

Authority

ES

Spain

Prior art keywords

antibody

cells

human

antibodies

lymphoma

Prior art date

2002-10-17

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired - Lifetime

Links

• Espacenet
• Global Dossier
• Discuss

• 241000282414 Homo sapiens Species 0.000 title claims abstract description 404
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 title claims abstract description 301
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 title claims abstract description 300
• 230000004540 complement-dependent cytotoxicity Effects 0.000 claims abstract description 69
• 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 54
• 230000000295 complement effect Effects 0.000 claims abstract description 41
• 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 claims abstract description 25
• 150000001413 amino acids Chemical class 0.000 claims abstract description 13
• 230000001939 inductive effect Effects 0.000 claims abstract description 12
• 210000004027 cell Anatomy 0.000 claims description 643
• 230000027455 binding Effects 0.000 claims description 160
• 239000000203 mixture Substances 0.000 claims description 100
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 87
• 238000000034 method Methods 0.000 claims description 77
• 239000000427 antigen Substances 0.000 claims description 72
• 108091007433 antigens Proteins 0.000 claims description 71
• 102000036639 antigens Human genes 0.000 claims description 71
• 239000012636 effector Substances 0.000 claims description 61
• 230000009261 transgenic effect Effects 0.000 claims description 61
• 108060003951 Immunoglobulin Proteins 0.000 claims description 55
• 102000018358 immunoglobulin Human genes 0.000 claims description 55
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 53
• 206010025323 Lymphomas Diseases 0.000 claims description 44
• 239000003814 drug Substances 0.000 claims description 36
• 230000001404 mediated effect Effects 0.000 claims description 36
• 201000010099 disease Diseases 0.000 claims description 34
• 238000011282 treatment Methods 0.000 claims description 34
• 206010028980 Neoplasm Diseases 0.000 claims description 31
• 239000003795 chemical substances by application Substances 0.000 claims description 27
• 150000007523 nucleic acids Chemical class 0.000 claims description 27
• 229940127121 immunoconjugate Drugs 0.000 claims description 24
• 238000004519 manufacturing process Methods 0.000 claims description 24
• 102000039446 nucleic acids Human genes 0.000 claims description 24
• 108020004707 nucleic acids Proteins 0.000 claims description 24
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
• 102000009109 Fc receptors Human genes 0.000 claims description 22
• 108010087819 Fc receptors Proteins 0.000 claims description 22
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 22
• 229940124597 therapeutic agent Drugs 0.000 claims description 22
• 210000004698 lymphocyte Anatomy 0.000 claims description 21
• 239000002773 nucleotide Substances 0.000 claims description 21
• 125000003729 nucleotide group Chemical group 0.000 claims description 21
• 239000013604 expression vector Substances 0.000 claims description 20
• 238000002560 therapeutic procedure Methods 0.000 claims description 20
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 18
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 18
• 201000003444 follicular lymphoma Diseases 0.000 claims description 18
• 238000000338 in vitro Methods 0.000 claims description 17
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
• 229920001184 polypeptide Polymers 0.000 claims description 16
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 16
• 230000006378 damage Effects 0.000 claims description 15
• 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 claims description 14
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 14
• 231100000599 cytotoxic agent Toxicity 0.000 claims description 14
• 208000023275 Autoimmune disease Diseases 0.000 claims description 12
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 12
• 239000003018 immunosuppressive agent Substances 0.000 claims description 12
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 11
• 229940127089 cytotoxic agent Drugs 0.000 claims description 11
• 229940079593 drug Drugs 0.000 claims description 11
• 230000012010 growth Effects 0.000 claims description 11
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 10
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 10
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 10
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 10
• 201000004624 Dermatitis Diseases 0.000 claims description 9
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 9
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 9
• 201000009594 Systemic Scleroderma Diseases 0.000 claims description 9
• 206010042953 Systemic sclerosis Diseases 0.000 claims description 9
• 230000001154 acute effect Effects 0.000 claims description 9
• 230000010261 cell growth Effects 0.000 claims description 9
• 229960004397 cyclophosphamide Drugs 0.000 claims description 9
• 208000026278 immune system disease Diseases 0.000 claims description 9
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
• 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 claims description 8
• 102000004127 Cytokines Human genes 0.000 claims description 8
• 108090000695 Cytokines Proteins 0.000 claims description 8
• 230000015572 biosynthetic process Effects 0.000 claims description 8
• 239000002254 cytotoxic agent Substances 0.000 claims description 8
• 108020001507 fusion proteins Proteins 0.000 claims description 8
• 102000037865 fusion proteins Human genes 0.000 claims description 8
• 210000000987 immune system Anatomy 0.000 claims description 8
• 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 7
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 7
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
• 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 7
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 7
• 229960004630 chlorambucil Drugs 0.000 claims description 7
• 229960004679 doxorubicin Drugs 0.000 claims description 7
• 229940125721 immunosuppressive agent Drugs 0.000 claims description 7
• 201000000050 myeloid neoplasm Diseases 0.000 claims description 7
• 230000003393 splenic effect Effects 0.000 claims description 7
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 6
• 108010006654 Bleomycin Proteins 0.000 claims description 6
• 208000011691 Burkitt lymphomas Diseases 0.000 claims description 6
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 6
• 108010036949 Cyclosporine Proteins 0.000 claims description 6
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 6
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 6
• 208000006673 asthma Diseases 0.000 claims description 6
• 229960005243 carmustine Drugs 0.000 claims description 6
• 230000001684 chronic effect Effects 0.000 claims description 6
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 6
• 229960004316 cisplatin Drugs 0.000 claims description 6
• 239000003937 drug carrier Substances 0.000 claims description 6
• 230000003325 follicular Effects 0.000 claims description 6
• 208000007475 hemolytic anemia Diseases 0.000 claims description 6
• 201000008383 nephritis Diseases 0.000 claims description 6
• 208000003950 B-cell lymphoma Diseases 0.000 claims description 5
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
• 208000011231 Crohn disease Diseases 0.000 claims description 5
• 206010018364 Glomerulonephritis Diseases 0.000 claims description 5
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 5
• 108091008874 T cell receptors Proteins 0.000 claims description 5
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 5
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 5
• 208000010668 atopic eczema Diseases 0.000 claims description 5
• 229960001561 bleomycin Drugs 0.000 claims description 5
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 5
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 5
• 208000025750 heavy chain disease Diseases 0.000 claims description 5
• 229960003444 immunosuppressant agent Drugs 0.000 claims description 5
• 201000006747 infectious mononucleosis Diseases 0.000 claims description 5
• 206010025135 lupus erythematosus Diseases 0.000 claims description 5
• 230000000527 lymphocytic effect Effects 0.000 claims description 5
• 210000003519 mature b lymphocyte Anatomy 0.000 claims description 5
• 229960000485 methotrexate Drugs 0.000 claims description 5
• 201000006417 multiple sclerosis Diseases 0.000 claims description 5
• 230000002265 prevention Effects 0.000 claims description 5
• 230000002285 radioactive effect Effects 0.000 claims description 5
• 208000002574 reactive arthritis Diseases 0.000 claims description 5
• 208000011580 syndromic disease Diseases 0.000 claims description 5
• 206010043554 thrombocytopenia Diseases 0.000 claims description 5
• 201000001320 Atherosclerosis Diseases 0.000 claims description 4
• 208000027496 Behcet disease Diseases 0.000 claims description 4
• 208000015023 Graves' disease Diseases 0.000 claims description 4
• 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 4
• 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 4
• 206010021263 IgA nephropathy Diseases 0.000 claims description 4
• 201000001779 Leukocyte adhesion deficiency Diseases 0.000 claims description 4
• 201000009906 Meningitis Diseases 0.000 claims description 4
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 4
• 241000721454 Pemphigus Species 0.000 claims description 4
• 208000007452 Plasmacytoma Diseases 0.000 claims description 4
• 206010036105 Polyneuropathy Diseases 0.000 claims description 4
• 201000004681 Psoriasis Diseases 0.000 claims description 4
• 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
• 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
• 208000003782 Raynaud disease Diseases 0.000 claims description 4
• 208000012322 Raynaud phenomenon Diseases 0.000 claims description 4
• 208000033464 Reiter syndrome Diseases 0.000 claims description 4
• 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
• 206010046851 Uveitis Diseases 0.000 claims description 4
• 206010003246 arthritis Diseases 0.000 claims description 4
• 208000020832 chronic kidney disease Diseases 0.000 claims description 4
• 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 4
• 229960001265 ciclosporin Drugs 0.000 claims description 4
• 229930182912 cyclosporin Natural products 0.000 claims description 4
• 206010014599 encephalitis Diseases 0.000 claims description 4
• 210000002865 immune cell Anatomy 0.000 claims description 4
• 230000001861 immunosuppressant effect Effects 0.000 claims description 4
• 208000027866 inflammatory disease Diseases 0.000 claims description 4
• 208000032839 leukemia Diseases 0.000 claims description 4
• 208000003747 lymphoid leukemia Diseases 0.000 claims description 4
• 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims description 4
• 206010028417 myasthenia gravis Diseases 0.000 claims description 4
• 230000007824 polyneuropathy Effects 0.000 claims description 4
• 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 claims description 4
• 210000001948 pro-b lymphocyte Anatomy 0.000 claims description 4
• 208000002491 severe combined immunodeficiency Diseases 0.000 claims description 4
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
• 241001529453 unidentified herpesvirus Species 0.000 claims description 4
• 208000023328 Basedow disease Diseases 0.000 claims description 3
• 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
• 208000005777 Lupus Nephritis Diseases 0.000 claims description 3
• 208000034578 Multiple myelomas Diseases 0.000 claims description 3
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
• 201000008937 atopic dermatitis Diseases 0.000 claims description 3
• 230000002401 inhibitory effect Effects 0.000 claims description 3
• 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
• 208000017604 Hodgkin disease Diseases 0.000 claims description 2
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 2
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 2
• 206010012601 diabetes mellitus Diseases 0.000 claims description 2
• 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
• 230000000366 juvenile effect Effects 0.000 claims description 2
• 210000004180 plasmocyte Anatomy 0.000 claims description 2
• 230000009885 systemic effect Effects 0.000 claims description 2
• 241000725303 Human immunodeficiency virus Species 0.000 claims 2
• 206010065857 Primary Effusion Lymphoma Diseases 0.000 claims 2
• 206010002412 Angiocentric lymphomas Diseases 0.000 claims 1
• 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
• 102000019034 Chemokines Human genes 0.000 claims 1
• 108010012236 Chemokines Proteins 0.000 claims 1
• 241000411532 Erites Species 0.000 claims 1
• 101001002508 Homo sapiens Immunoglobulin-binding protein 1 Proteins 0.000 claims 1
• 102100021042 Immunoglobulin-binding protein 1 Human genes 0.000 claims 1
• 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 1
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
• 230000002519 immonomodulatory effect Effects 0.000 claims 1
• 210000000936 intestine Anatomy 0.000 claims 1
• 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 1
• 210000002751 lymph Anatomy 0.000 claims 1
• 208000006116 lymphomatoid granulomatosis Diseases 0.000 claims 1
• 230000009826 neoplastic cell growth Effects 0.000 claims 1
• 229960004641 rituximab Drugs 0.000 description 139
• 108090000623 proteins and genes Proteins 0.000 description 101
• 230000009089 cytolysis Effects 0.000 description 98
• 108700019146 Transgenes Proteins 0.000 description 70
• 241001465754 Metazoa Species 0.000 description 50
• 241000699670 Mus sp. Species 0.000 description 50
• 238000000684 flow cytometry Methods 0.000 description 50
• 241000699666 Mus <mouse, genus> Species 0.000 description 45
• 150000001875 compounds Chemical class 0.000 description 38
• 238000007792 addition Methods 0.000 description 35
• 230000006907 apoptotic process Effects 0.000 description 34
• 230000014509 gene expression Effects 0.000 description 34
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 33
• 210000004369 blood Anatomy 0.000 description 33
• 239000008280 blood Substances 0.000 description 33
• 230000000694 effects Effects 0.000 description 33
• 238000002474 experimental method Methods 0.000 description 33
• 210000002966 serum Anatomy 0.000 description 33
• 210000004602 germ cell Anatomy 0.000 description 32
• 230000006037 cell lysis Effects 0.000 description 31
• 239000012634 fragment Substances 0.000 description 31
• 239000013598 vector Substances 0.000 description 30
• 210000004408 hybridoma Anatomy 0.000 description 29
• 235000018102 proteins Nutrition 0.000 description 29
• 102000004169 proteins and genes Human genes 0.000 description 29
• 210000005087 mononuclear cell Anatomy 0.000 description 28
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 28
• 230000001225 therapeutic effect Effects 0.000 description 28
• 229940027941 immunoglobulin g Drugs 0.000 description 26
• 238000011534 incubation Methods 0.000 description 25
• 108020004414 DNA Proteins 0.000 description 24
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 23
• 210000004881 tumor cell Anatomy 0.000 description 22
• 238000002360 preparation method Methods 0.000 description 21
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 19
• 238000011579 SCID mouse model Methods 0.000 description 19
• 208000035475 disorder Diseases 0.000 description 19
• 239000002609 medium Substances 0.000 description 19
• 239000000523 sample Substances 0.000 description 19
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 18
• 239000013612 plasmid Substances 0.000 description 18
• 239000000243 solution Substances 0.000 description 18
• 238000010494 dissociation reaction Methods 0.000 description 17
• 230000005593 dissociations Effects 0.000 description 17
• 238000001727 in vivo Methods 0.000 description 17
• 238000003752 polymerase chain reaction Methods 0.000 description 17
• 238000011830 transgenic mouse model Methods 0.000 description 17
• 102100039487 Deoxyhypusine hydroxylase Human genes 0.000 description 16
• 108010028753 deoxyhypusine hydroxylase Proteins 0.000 description 16
• -1 for example Proteins 0.000 description 16
• 230000006698 induction Effects 0.000 description 16
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
• 102100025680 Complement decay-accelerating factor Human genes 0.000 description 15
• 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 15
• 238000004458 analytical method Methods 0.000 description 15
• 238000002866 fluorescence resonance energy transfer Methods 0.000 description 15
• 230000006870 function Effects 0.000 description 15
• 229940098773 bovine serum albumin Drugs 0.000 description 14
• 238000001802 infusion Methods 0.000 description 14
• 230000006798 recombination Effects 0.000 description 14
• 238000005215 recombination Methods 0.000 description 14
• 230000004083 survival effect Effects 0.000 description 14
• 238000002965 ELISA Methods 0.000 description 13
• 235000001014 amino acid Nutrition 0.000 description 13
• 238000000540 analysis of variance Methods 0.000 description 13
• 238000011156 evaluation Methods 0.000 description 13
• 239000008194 pharmaceutical composition Substances 0.000 description 13
• 241000894007 species Species 0.000 description 13
• 238000012449 Kunming mouse Methods 0.000 description 12
• 239000013504 Triton X-100 Substances 0.000 description 12
• 229920004890 Triton X-100 Polymers 0.000 description 12
• 229940024606 amino acid Drugs 0.000 description 12
• 125000000539 amino acid group Chemical group 0.000 description 12
• 230000001419 dependent effect Effects 0.000 description 12
• 230000003053 immunization Effects 0.000 description 12
• 238000012360 testing method Methods 0.000 description 12
• 108010073807 IgG Receptors Proteins 0.000 description 11
• 102000009490 IgG Receptors Human genes 0.000 description 11
• 241001529936 Murinae Species 0.000 description 11
• 206010057249 Phagocytosis Diseases 0.000 description 11
• 230000002776 aggregation Effects 0.000 description 11
• 238000004220 aggregation Methods 0.000 description 11
• 230000004927 fusion Effects 0.000 description 11
• 150000002632 lipids Chemical class 0.000 description 11
• 239000012528 membrane Substances 0.000 description 11
• 210000000440 neutrophil Anatomy 0.000 description 11
• 239000013615 primer Substances 0.000 description 11
• 229940124292 CD20 monoclonal antibody Drugs 0.000 description 10
• 108020004635 Complementary DNA Proteins 0.000 description 10
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 10
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 10
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 10
• 239000000370 acceptor Substances 0.000 description 10
• 238000003556 assay Methods 0.000 description 10
• 238000010804 cDNA synthesis Methods 0.000 description 10
• 239000002299 complementary DNA Substances 0.000 description 10
• 238000002649 immunization Methods 0.000 description 10
• 229940072221 immunoglobulins Drugs 0.000 description 10
• 238000002347 injection Methods 0.000 description 10
• 239000007924 injection Substances 0.000 description 10
• 239000002502 liposome Substances 0.000 description 10
• 210000002540 macrophage Anatomy 0.000 description 10
• 230000008782 phagocytosis Effects 0.000 description 10
• 239000006228 supernatant Substances 0.000 description 10
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 9
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 9
• 239000002552 dosage form Substances 0.000 description 9
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 9
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 9
• 238000001990 intravenous administration Methods 0.000 description 9
• 210000001616 monocyte Anatomy 0.000 description 9
• 238000002703 mutagenesis Methods 0.000 description 9
• 231100000350 mutagenesis Toxicity 0.000 description 9
• 239000000047 product Substances 0.000 description 9
• 102000005962 receptors Human genes 0.000 description 9
• 108020003175 receptors Proteins 0.000 description 9
• 150000003839 salts Chemical class 0.000 description 9
• 231100000588 tumorigenic Toxicity 0.000 description 9
• 230000000381 tumorigenic effect Effects 0.000 description 9
• 206010069754 Acquired gene mutation Diseases 0.000 description 8
• 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 8
• 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 8
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
• 230000001472 cytotoxic effect Effects 0.000 description 8
• 239000012894 fetal calf serum Substances 0.000 description 8
• 238000009472 formulation Methods 0.000 description 8
• 229940099472 immunoglobulin a Drugs 0.000 description 8
• 230000006872 improvement Effects 0.000 description 8
• 210000001165 lymph node Anatomy 0.000 description 8
• 230000007246 mechanism Effects 0.000 description 8
• 210000005259 peripheral blood Anatomy 0.000 description 8
• 239000011886 peripheral blood Substances 0.000 description 8
• 230000001105 regulatory effect Effects 0.000 description 8
• 230000004044 response Effects 0.000 description 8
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 8
• 230000037439 somatic mutation Effects 0.000 description 8
• 239000003981 vehicle Substances 0.000 description 8
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
• 101150013553 CD40 gene Proteins 0.000 description 7
• 102100022002 CD59 glycoprotein Human genes 0.000 description 7
• 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 7
• 108010074328 Interferon-gamma Proteins 0.000 description 7
• 241000282567 Macaca fascicularis Species 0.000 description 7
• 108091034117 Oligonucleotide Proteins 0.000 description 7
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 7
• 238000010521 absorption reaction Methods 0.000 description 7
• 239000002246 antineoplastic agent Substances 0.000 description 7
• 238000010367 cloning Methods 0.000 description 7
• 238000007796 conventional method Methods 0.000 description 7
• 230000004069 differentiation Effects 0.000 description 7
• 239000006185 dispersion Substances 0.000 description 7
• 230000028993 immune response Effects 0.000 description 7
• 230000006882 induction of apoptosis Effects 0.000 description 7
• 230000035772 mutation Effects 0.000 description 7
• 230000036961 partial effect Effects 0.000 description 7
• 229920001223 polyethylene glycol Polymers 0.000 description 7
• 230000003389 potentiating effect Effects 0.000 description 7
• 230000002035 prolonged effect Effects 0.000 description 7
• 238000005406 washing Methods 0.000 description 7
• 108090000672 Annexin A5 Proteins 0.000 description 6
• 102000004121 Annexin A5 Human genes 0.000 description 6
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 6
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 6
• 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 6
• 238000012408 PCR amplification Methods 0.000 description 6
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 239000004480 active ingredient Substances 0.000 description 6
• 238000005119 centrifugation Methods 0.000 description 6
• 238000010276 construction Methods 0.000 description 6
• 239000002619 cytotoxin Substances 0.000 description 6
• 238000012377 drug delivery Methods 0.000 description 6
• 230000013595 glycosylation Effects 0.000 description 6
• 238000006206 glycosylation reaction Methods 0.000 description 6
• 238000003384 imaging method Methods 0.000 description 6
• 230000004048 modification Effects 0.000 description 6
• 238000012986 modification Methods 0.000 description 6
• 230000009467 reduction Effects 0.000 description 6
• 230000005945 translocation Effects 0.000 description 6
• 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 description 5
• 241000196324 Embryophyta Species 0.000 description 5
• 102000004190 Enzymes Human genes 0.000 description 5
• 108090000790 Enzymes Proteins 0.000 description 5
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
• 108010042653 IgA receptor Proteins 0.000 description 5
• 241000699660 Mus musculus Species 0.000 description 5
• 239000012980 RPMI-1640 medium Substances 0.000 description 5
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
• 239000004473 Threonine Substances 0.000 description 5
• 101150117115 V gene Proteins 0.000 description 5
• 241000700605 Viruses Species 0.000 description 5
• 239000002671 adjuvant Substances 0.000 description 5
• 230000001413 cellular effect Effects 0.000 description 5
• 230000008859 change Effects 0.000 description 5
• 238000012512 characterization method Methods 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
• 239000011248 coating agent Substances 0.000 description 5
• 238000000576 coating method Methods 0.000 description 5
• 238000012217 deletion Methods 0.000 description 5
• 230000037430 deletion Effects 0.000 description 5
• 238000009826 distribution Methods 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 238000004128 high performance liquid chromatography Methods 0.000 description 5
• 238000009396 hybridization Methods 0.000 description 5
• 230000001976 improved effect Effects 0.000 description 5
• 238000007912 intraperitoneal administration Methods 0.000 description 5
• 230000003211 malignant effect Effects 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 244000005700 microbiome Species 0.000 description 5
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
• 230000000144 pharmacologic effect Effects 0.000 description 5
• 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 description 5
• 238000003127 radioimmunoassay Methods 0.000 description 5
• 230000008707 rearrangement Effects 0.000 description 5
• 230000010076 replication Effects 0.000 description 5
• 238000004114 suspension culture Methods 0.000 description 5
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
• 241000588724 Escherichia coli Species 0.000 description 4
• 108010040476 FITC-annexin A5 Proteins 0.000 description 4
• 229920001917 Ficoll Polymers 0.000 description 4
• 241000233866 Fungi Species 0.000 description 4
• 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 4
• 238000012450 HuMAb Mouse Methods 0.000 description 4
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
• 102000008070 Interferon-gamma Human genes 0.000 description 4
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
• 108060001084 Luciferase Proteins 0.000 description 4
• 239000005089 Luciferase Substances 0.000 description 4
• 101710160107 Outer membrane protein A Proteins 0.000 description 4
• 206010033799 Paralysis Diseases 0.000 description 4
• 239000002202 Polyethylene glycol Substances 0.000 description 4
• 108010029485 Protein Isoforms Proteins 0.000 description 4
• 102000001708 Protein Isoforms Human genes 0.000 description 4
• 150000007513 acids Chemical class 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 230000009830 antibody antigen interaction Effects 0.000 description 4
• 239000011230 binding agent Substances 0.000 description 4
• 230000004071 biological effect Effects 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 201000011510 cancer Diseases 0.000 description 4
• 239000004074 complement inhibitor Substances 0.000 description 4
• 239000013068 control sample Substances 0.000 description 4
• 230000001461 cytolytic effect Effects 0.000 description 4
• 231100000433 cytotoxic Toxicity 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• 239000000787 lecithin Substances 0.000 description 4
• 229940067606 lecithin Drugs 0.000 description 4
• 235000010445 lecithin Nutrition 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 239000011159 matrix material Substances 0.000 description 4
• 239000003921 oil Substances 0.000 description 4
• 235000019198 oils Nutrition 0.000 description 4
• 238000011275 oncology therapy Methods 0.000 description 4
• 238000001543 one-way ANOVA Methods 0.000 description 4
• 239000008188 pellet Substances 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 229920006395 saturated elastomer Polymers 0.000 description 4
• 238000000926 separation method Methods 0.000 description 4
• 238000012163 sequencing technique Methods 0.000 description 4
• 229940054269 sodium pyruvate Drugs 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 230000003068 static effect Effects 0.000 description 4
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
• 238000007920 subcutaneous administration Methods 0.000 description 4
• 238000006467 substitution reaction Methods 0.000 description 4
• 239000004094 surface-active agent Substances 0.000 description 4
• 239000003104 tissue culture media Substances 0.000 description 4
• 238000001890 transfection Methods 0.000 description 4
• 230000004614 tumor growth Effects 0.000 description 4
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
• 229960004528 vincristine Drugs 0.000 description 4
• 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 3
• 102100032768 Complement receptor type 2 Human genes 0.000 description 3
• 101710112752 Cytotoxin Proteins 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• 241000287828 Gallus gallus Species 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 3
• 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 3
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
• 102100037850 Interferon gamma Human genes 0.000 description 3
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 229920002684 Sepharose Polymers 0.000 description 3
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
• 206010047115 Vasculitis Diseases 0.000 description 3
• 238000000246 agarose gel electrophoresis Methods 0.000 description 3
• 230000007720 allelic exclusion Effects 0.000 description 3
• 230000004075 alteration Effects 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 239000002260 anti-inflammatory agent Substances 0.000 description 3
• 229940121363 anti-inflammatory agent Drugs 0.000 description 3
• 229940034982 antineoplastic agent Drugs 0.000 description 3
• 239000003963 antioxidant agent Substances 0.000 description 3
• 235000006708 antioxidants Nutrition 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 230000029918 bioluminescence Effects 0.000 description 3
• 238000005415 bioluminescence Methods 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 230000008499 blood brain barrier function Effects 0.000 description 3
• 210000001218 blood-brain barrier Anatomy 0.000 description 3
• 210000000170 cell membrane Anatomy 0.000 description 3
• 235000013330 chicken meat Nutrition 0.000 description 3
• 210000000349 chromosome Anatomy 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 239000013599 cloning vector Substances 0.000 description 3
• 230000024203 complement activation Effects 0.000 description 3
• 230000009918 complex formation Effects 0.000 description 3
• 230000021615 conjugation Effects 0.000 description 3
• 230000001276 controlling effect Effects 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 239000002612 dispersion medium Substances 0.000 description 3
• 231100000673 dose–response relationship Toxicity 0.000 description 3
• 239000000975 dye Substances 0.000 description 3
• 238000004520 electroporation Methods 0.000 description 3
• 239000003623 enhancer Substances 0.000 description 3
• 230000007717 exclusion Effects 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• 230000009036 growth inhibition Effects 0.000 description 3
• 239000002596 immunotoxin Substances 0.000 description 3
• 239000007943 implant Substances 0.000 description 3
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 3
• 239000000411 inducer Substances 0.000 description 3
• 230000002757 inflammatory effect Effects 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• 229960003130 interferon gamma Drugs 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 239000007951 isotonicity adjuster Substances 0.000 description 3
• 239000003446 ligand Substances 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 210000003141 lower extremity Anatomy 0.000 description 3
• 238000012423 maintenance Methods 0.000 description 3
• 239000013642 negative control Substances 0.000 description 3
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 238000000399 optical microscopy Methods 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
• XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 3
• 229920005862 polyol Polymers 0.000 description 3
• 150000003077 polyols Chemical class 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 238000003259 recombinant expression Methods 0.000 description 3
• 238000010188 recombinant method Methods 0.000 description 3
• 239000006152 selective media Substances 0.000 description 3
• 230000035945 sensitivity Effects 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 210000004988 splenocyte Anatomy 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 235000000346 sugar Nutrition 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 210000003462 vein Anatomy 0.000 description 3
• 238000001262 western blot Methods 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
• KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
• 201000004384 Alopecia Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 206010055128 Autoimmune neutropenia Diseases 0.000 description 2
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
• 206010057248 Cell death Diseases 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• 102000053602 DNA Human genes 0.000 description 2
• 108010092160 Dactinomycin Proteins 0.000 description 2
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
• 206010015226 Erythema nodosum Diseases 0.000 description 2
• 108010008165 Etanercept Proteins 0.000 description 2
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 239000007995 HEPES buffer Substances 0.000 description 2
• 208000008899 Habitual abortion Diseases 0.000 description 2
• 241000238631 Hexapoda Species 0.000 description 2
• 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 2
• 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 2
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
• 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 2
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
• 102000000589 Interleukin-1 Human genes 0.000 description 2
• 108010002352 Interleukin-1 Proteins 0.000 description 2
• 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
• 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 102000004889 Interleukin-6 Human genes 0.000 description 2
• 108090001005 Interleukin-6 Proteins 0.000 description 2
• 102100026019 Interleukin-6 Human genes 0.000 description 2
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
• 229930182816 L-glutamine Natural products 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 2
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
• 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 2
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
• 206010052178 Lymphocytic lymphoma Diseases 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 2
• 239000000020 Nitrocellulose Substances 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• 206010034277 Pemphigoid Diseases 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 240000004350 Prunus spinosa Species 0.000 description 2
• 235000010829 Prunus spinosa Nutrition 0.000 description 2
• 108010039491 Ricin Proteins 0.000 description 2
• 206010070834 Sensitisation Diseases 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 2
• 210000001744 T-lymphocyte Anatomy 0.000 description 2
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
• 102100040247 Tumor necrosis factor Human genes 0.000 description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
• 239000011543 agarose gel Substances 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 125000001931 aliphatic group Chemical group 0.000 description 2
• 231100000360 alopecia Toxicity 0.000 description 2
• 229940045799 anthracyclines and related substance Drugs 0.000 description 2
• VGQOVCHZGQWAOI-YQRHFANHSA-N anthramycin Chemical compound N1[C@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-YQRHFANHSA-N 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 239000003429 antifungal agent Substances 0.000 description 2
• 229940121375 antifungal agent Drugs 0.000 description 2
• 229950006345 antramycin Drugs 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 239000012148 binding buffer Substances 0.000 description 2
• 210000000601 blood cell Anatomy 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 239000007975 buffered saline Substances 0.000 description 2
• 208000000594 bullous pemphigoid Diseases 0.000 description 2
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
• 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
• AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 239000012876 carrier material Substances 0.000 description 2
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 238000012412 chemical coupling Methods 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 201000004709 chorioretinitis Diseases 0.000 description 2
• 239000013611 chromosomal DNA Substances 0.000 description 2
• 238000011260 co-administration Methods 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 230000004154 complement system Effects 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• 239000003431 cross linking reagent Substances 0.000 description 2
• 230000009260 cross reactivity Effects 0.000 description 2
• 239000012228 culture supernatant Substances 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 208000037765 diseases and disorders Diseases 0.000 description 2
• 229960000284 efalizumab Drugs 0.000 description 2
• 210000003979 eosinophil Anatomy 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
• 229960000390 fludarabine Drugs 0.000 description 2
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
• 238000000799 fluorescence microscopy Methods 0.000 description 2
• 239000007850 fluorescent dye Substances 0.000 description 2
• 238000001502 gel electrophoresis Methods 0.000 description 2
• 238000012215 gene cloning Methods 0.000 description 2
• 238000010353 genetic engineering Methods 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 210000003714 granulocyte Anatomy 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 238000002744 homologous recombination Methods 0.000 description 2
• 230000006801 homologous recombination Effects 0.000 description 2
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
• 210000000962 igg plasma cell Anatomy 0.000 description 2
• 229940121354 immunomodulator Drugs 0.000 description 2
• 238000009169 immunotherapy Methods 0.000 description 2
• 230000002637 immunotoxin Effects 0.000 description 2
• 229940051026 immunotoxin Drugs 0.000 description 2
• 231100000608 immunotoxin Toxicity 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 239000007972 injectable composition Substances 0.000 description 2
• 238000011081 inoculation Methods 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
• 239000012139 lysis buffer Substances 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 238000013507 mapping Methods 0.000 description 2
• 230000035800 maturation Effects 0.000 description 2
• 210000003622 mature neutrocyte Anatomy 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
• 229960004452 methionine Drugs 0.000 description 2
• 235000013336 milk Nutrition 0.000 description 2
• 239000008267 milk Substances 0.000 description 2
• 210000004080 milk Anatomy 0.000 description 2
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
• 229960004857 mitomycin Drugs 0.000 description 2
• 239000003068 molecular probe Substances 0.000 description 2
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
• 229960005027 natalizumab Drugs 0.000 description 2
• 229920001220 nitrocellulos Polymers 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 229920002113 octoxynol Polymers 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 230000003204 osmotic effect Effects 0.000 description 2
• OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
• 208000012111 paraneoplastic syndrome Diseases 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 239000006072 paste Substances 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
• 230000035699 permeability Effects 0.000 description 2
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
• 208000031223 plasma cell leukemia Diseases 0.000 description 2
• HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 2
• 229960003171 plicamycin Drugs 0.000 description 2
• 238000002600 positron emission tomography Methods 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
• 229960005205 prednisolone Drugs 0.000 description 2
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
• 229960004618 prednisone Drugs 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
• 229960004919 procaine Drugs 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 229950010131 puromycin Drugs 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 231100000336 radiotoxic Toxicity 0.000 description 2
• 230000001690 radiotoxic effect Effects 0.000 description 2
• 231100001258 radiotoxin Toxicity 0.000 description 2
• 230000000306 recurrent effect Effects 0.000 description 2
• 108091008146 restriction endonucleases Proteins 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 230000008313 sensitization Effects 0.000 description 2
• 239000012679 serum free medium Substances 0.000 description 2
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
• 210000001082 somatic cell Anatomy 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 150000005846 sugar alcohols Polymers 0.000 description 2
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 230000004797 therapeutic response Effects 0.000 description 2
• 206010043778 thyroiditis Diseases 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• 210000001519 tissue Anatomy 0.000 description 2
• 238000004448 titration Methods 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 229960003048 vinblastine Drugs 0.000 description 2
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
• 239000013603 viral vector Substances 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• 230000003442 weekly effect Effects 0.000 description 2
• 210000005253 yeast cell Anatomy 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
• FLCQLSRLQIPNLM-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-acetylsulfanylacetate Chemical compound CC(=O)SCC(=O)ON1C(=O)CCC1=O FLCQLSRLQIPNLM-UHFFFAOYSA-N 0.000 description 1
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
• VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 1
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
• MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
• NNYBQONXHNTVIJ-QGZVFWFLSA-N (R)-etodolac Chemical compound C1CO[C@](CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-QGZVFWFLSA-N 0.000 description 1
• PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
• 108020005345 3' Untranslated Regions Proteins 0.000 description 1
• WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
• WUIABRMSWOKTOF-OCBSMOPSSA-N 3-[[2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxym Chemical compound OS([O-])(=O)=O.N=1C(C=2SC=C(N=2)C(=O)NCCC[S+](C)C)=CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OCBSMOPSSA-N 0.000 description 1
• XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
• 102100026445 A-kinase anchor protein 17A Human genes 0.000 description 1
• 208000023769 AA amyloidosis Diseases 0.000 description 1
• 108010066676 Abrin Proteins 0.000 description 1
• 208000007815 Acquired Hyperostosis Syndrome Diseases 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 201000010000 Agranulocytosis Diseases 0.000 description 1
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
• 206010001889 Alveolitis Diseases 0.000 description 1
• 208000028185 Angioedema Diseases 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 208000032467 Aplastic anaemia Diseases 0.000 description 1
• 108010039627 Aprotinin Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 206010003267 Arthritis reactive Diseases 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 229930003347 Atropine Natural products 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 241000283724 Bison bonasus Species 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 201000002829 CREST Syndrome Diseases 0.000 description 1
• 101100022187 Caenorhabditis elegans mab-10 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 108090000312 Calcium Channels Proteins 0.000 description 1
• 102000003922 Calcium Channels Human genes 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 208000020446 Cardiac disease Diseases 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
• 206010008748 Chorea Diseases 0.000 description 1
• 206010008909 Chronic Hepatitis Diseases 0.000 description 1
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 208000015943 Coeliac disease Diseases 0.000 description 1
• 208000011038 Cold agglutinin disease Diseases 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 102000000989 Complement System Proteins Human genes 0.000 description 1
• 108010069112 Complement System Proteins Proteins 0.000 description 1
• 229940124073 Complement inhibitor Drugs 0.000 description 1
• 241000557626 Corvus corax Species 0.000 description 1
• 241000938605 Crocodylia Species 0.000 description 1
• 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
• 241000195493 Cryptophyta Species 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• 101150097493 D gene Proteins 0.000 description 1
• 206010012442 Dermatitis contact Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 241001269524 Dura Species 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
• 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
• 206010053177 Epidermolysis Diseases 0.000 description 1
• 206010015218 Erythema multiforme Diseases 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 229940124135 Factor VIII inhibitor Drugs 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• 108090000331 Firefly luciferases Proteins 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 206010070531 Foetal growth restriction Diseases 0.000 description 1
• 101150074355 GS gene Proteins 0.000 description 1
• 208000012841 Gamma-heavy chain disease Diseases 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 206010018374 Glomerulonephritis minimal lesion Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 108010026389 Gramicidin Proteins 0.000 description 1
• 102100030385 Granzyme B Human genes 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
• 208000023661 Haematological disease Diseases 0.000 description 1
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
• 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
• 208000031220 Hemophilia Diseases 0.000 description 1
• 208000009292 Hemophilia A Diseases 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 206010019755 Hepatitis chronic active Diseases 0.000 description 1
• 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
• 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101000718019 Homo sapiens A-kinase anchor protein 17A Proteins 0.000 description 1
• 101001009603 Homo sapiens Granzyme B Proteins 0.000 description 1
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
• 101000574992 Homo sapiens Mediator of RNA polymerase II transcription subunit 26 Proteins 0.000 description 1
• 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 208000013016 Hypoglycemia Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 102000003746 Insulin Receptor Human genes 0.000 description 1
• 108010001127 Insulin Receptor Proteins 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• 102100034343 Integrase Human genes 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
• 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
• 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
• 101150008942 J gene Proteins 0.000 description 1
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
• 208000009388 Job Syndrome Diseases 0.000 description 1
• 206010023232 Joint swelling Diseases 0.000 description 1
• 208000003456 Juvenile Arthritis Diseases 0.000 description 1
• 101150042441 K gene Proteins 0.000 description 1
• 208000011200 Kawasaki disease Diseases 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
• QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• 229930195722 L-methionine Natural products 0.000 description 1
• 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
• GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 208000001244 Linear IgA Bullous Dermatosis Diseases 0.000 description 1
• 208000004883 Lipoid Nephrosis Diseases 0.000 description 1
• 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 102100025546 Mediator of RNA polymerase II transcription subunit 26 Human genes 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
• 206010027910 Mononeuritis Diseases 0.000 description 1
• 208000012799 Mu-heavy chain disease Diseases 0.000 description 1
• 206010028372 Muscular weakness Diseases 0.000 description 1
• 206010028424 Myasthenic syndrome Diseases 0.000 description 1
• 206010028570 Myelopathy Diseases 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 238000011887 Necropsy Methods 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• 208000007944 Nodular Nonsuppurative Panniculitis Diseases 0.000 description 1
• 208000025047 Non-histaminic angioedema Diseases 0.000 description 1
• 108091005461 Nucleic proteins Chemical group 0.000 description 1
• 206010029888 Obliterative bronchiolitis Diseases 0.000 description 1
• 201000007142 Omenn syndrome Diseases 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 238000009004 PCR Kit Methods 0.000 description 1
• 206010053869 POEMS syndrome Diseases 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 206010033661 Pancytopenia Diseases 0.000 description 1
• 206010033885 Paraparesis Diseases 0.000 description 1
• 201000011152 Pemphigus Diseases 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 206010065159 Polychondritis Diseases 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 description 1
• 208000033766 Prolymphocytic Leukemia Diseases 0.000 description 1
• 241000125945 Protoparvovirus Species 0.000 description 1
• 108091008109 Pseudogenes Proteins 0.000 description 1
• 102000057361 Pseudogenes Human genes 0.000 description 1
• 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
• 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
• 206010037549 Purpura Diseases 0.000 description 1
• 241001672981 Purpura Species 0.000 description 1
• 208000006311 Pyoderma Diseases 0.000 description 1
• 108020005067 RNA Splice Sites Proteins 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 102000018120 Recombinases Human genes 0.000 description 1
• 108010091086 Recombinases Proteins 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 201000004854 SAPHO syndrome Diseases 0.000 description 1
• AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
• 206010039361 Sacroiliitis Diseases 0.000 description 1
• 206010039811 Secondary amyloidosis Diseases 0.000 description 1
• 229920005654 Sephadex Polymers 0.000 description 1
• 239000012507 Sephadex™ Substances 0.000 description 1
• 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
• 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
• OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
• 208000027522 Sydenham chorea Diseases 0.000 description 1
• 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
• 208000001106 Takayasu Arteritis Diseases 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
• 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
• 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
• 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
• 206010054094 Tumour necrosis Diseases 0.000 description 1
• GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 208000026736 Weber-Christian disease Diseases 0.000 description 1
• 208000027207 Whipple disease Diseases 0.000 description 1
• VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
• HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 229930183665 actinomycin Natural products 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 229960002964 adalimumab Drugs 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 229940013181 advil Drugs 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 208000004631 alopecia areata Diseases 0.000 description 1
• 208000025751 alpha chain disease Diseases 0.000 description 1
• 229940087168 alpha tocopherol Drugs 0.000 description 1
• PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 206010001902 amaurosis Diseases 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 238000012197 amplification kit Methods 0.000 description 1
• 229960004238 anakinra Drugs 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000000118 anti-neoplastic effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 238000011230 antibody-based therapy Methods 0.000 description 1
• 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000003080 antimitotic agent Substances 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 229960004405 aprotinin Drugs 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 229940059756 arava Drugs 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 238000000149 argon plasma sintering Methods 0.000 description 1
• 159000000032 aromatic acids Chemical class 0.000 description 1
• 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 230000000712 assembly Effects 0.000 description 1
• 238000000429 assembly Methods 0.000 description 1
• RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
• 229960000396 atropine Drugs 0.000 description 1
• 201000005000 autoimmune gastritis Diseases 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 201000004339 autoimmune neuropathy Diseases 0.000 description 1
• 238000000376 autoradiography Methods 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 150000001540 azides Chemical class 0.000 description 1
• 244000052616 bacterial pathogen Species 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 230000008033 biological extinction Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 201000003848 bronchiolitis obliterans Diseases 0.000 description 1
• 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• 150000001720 carbohydrates Chemical group 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000005018 casein Substances 0.000 description 1
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
• 235000021240 caseins Nutrition 0.000 description 1
• 229940047495 celebrex Drugs 0.000 description 1
• 229960000590 celecoxib Drugs 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 230000005889 cellular cytotoxicity Effects 0.000 description 1
• 208000011235 central nervous system lupus Diseases 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
• 229960002023 chloroprocaine Drugs 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 208000024376 chronic urticaria Diseases 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 229960001338 colchicine Drugs 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 230000005757 colony formation Effects 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 238000011220 combination immunotherapy Methods 0.000 description 1
• 230000001143 conditioned effect Effects 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 208000018631 connective tissue disease Diseases 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 208000010247 contact dermatitis Diseases 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 239000000599 controlled substance Substances 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 239000007822 coupling agent Substances 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 229960002433 cysteine Drugs 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 229960001305 cysteine hydrochloride Drugs 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
• GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
• 238000004163 cytometry Methods 0.000 description 1
• 208000024389 cytopenia Diseases 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 238000013480 data collection Methods 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 229940070230 daypro Drugs 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 206010061811 demyelinating polyneuropathy Diseases 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 229960001259 diclofenac Drugs 0.000 description 1
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
• KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• 229960000616 diflunisal Drugs 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 229940072701 dolobid Drugs 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 235000013601 eggs Nutrition 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
• 229960002694 emetine Drugs 0.000 description 1
• AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 229940073621 enbrel Drugs 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 208000030172 endocrine system disease Diseases 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000007515 enzymatic degradation Effects 0.000 description 1
• 210000000222 eosinocyte Anatomy 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 229960000403 etanercept Drugs 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 229940012017 ethylenediamine Drugs 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 238000009313 farming Methods 0.000 description 1
• 229960001419 fenoprofen Drugs 0.000 description 1
• RDJGLLICXDHJDY-UHFFFAOYSA-N fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 208000030941 fetal growth restriction Diseases 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 229940014144 folate Drugs 0.000 description 1
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 229940044627 gamma-interferon Drugs 0.000 description 1
• 238000005227 gel permeation chromatography Methods 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 238000012637 gene transfection Methods 0.000 description 1
• 229960002518 gentamicin Drugs 0.000 description 1
• 229940084910 gliadel Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 150000002337 glycosamines Chemical group 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 230000002949 hemolytic effect Effects 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 229940096329 human immunoglobulin a Drugs 0.000 description 1
• BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
• 150000002433 hydrophilic molecules Chemical class 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 229960004171 hydroxychloroquine Drugs 0.000 description 1
• 206010051040 hyper-IgE syndrome Diseases 0.000 description 1
• 208000005795 hyperglobulinemic purpura Diseases 0.000 description 1
• 230000002218 hypoglycaemic effect Effects 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 208000013397 idiopathic acute eosinophilic pneumonia Diseases 0.000 description 1
• 239000012642 immune effector Substances 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 230000000415 inactivating effect Effects 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 201000008319 inclusion body myositis Diseases 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 229940055742 indium-111 Drugs 0.000 description 1
• APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
• 229940089536 indocin Drugs 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 229960000598 infliximab Drugs 0.000 description 1
• 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000003426 interchromosomal effect Effects 0.000 description 1
• 229940100601 interleukin-6 Drugs 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 230000000155 isotopic effect Effects 0.000 description 1
• 210000001503 joint Anatomy 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• 229960000991 ketoprofen Drugs 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 229940054136 kineret Drugs 0.000 description 1
• 238000012332 laboratory investigation Methods 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 229960000681 leflunomide Drugs 0.000 description 1
• 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
• 108010052968 leupeptin Proteins 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 108020001756 ligand binding domains Proteins 0.000 description 1
• 208000029631 linear IgA Dermatosis Diseases 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 210000005210 lymphoid organ Anatomy 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 238000009115 maintenance therapy Methods 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 150000008146 mannosides Chemical class 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 210000002284 membrane microdomain Anatomy 0.000 description 1
• 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 238000001471 micro-filtration Methods 0.000 description 1
• 206010063344 microscopic polyangiitis Diseases 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 208000013734 mononeuritis simplex Diseases 0.000 description 1
• 201000005518 mononeuropathy Diseases 0.000 description 1
• 229940072709 motrin Drugs 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 208000026114 mu chain disease Diseases 0.000 description 1
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
• 230000036473 myasthenia Effects 0.000 description 1
• 229960004270 nabumetone Drugs 0.000 description 1
• 229940089466 nalfon Drugs 0.000 description 1
• 229940090008 naprosyn Drugs 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 230000017066 negative regulation of growth Effects 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 229940063121 neoral Drugs 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 230000001254 nonsecretory effect Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 230000005257 nucleotidylation Effects 0.000 description 1
• 208000036236 obstetric disease Diseases 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 231100000590 oncogenic Toxicity 0.000 description 1
• 230000002246 oncogenic effect Effects 0.000 description 1
• 230000014207 opsonization Effects 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 238000012634 optical imaging Methods 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 229960002739 oxaprozin Drugs 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 230000000242 pagocytic effect Effects 0.000 description 1
• 206010033675 panniculitis Diseases 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 201000001976 pemphigus vulgaris Diseases 0.000 description 1
• 208000008494 pericarditis Diseases 0.000 description 1
• 210000004976 peripheral blood cell Anatomy 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 238000002823 phage display Methods 0.000 description 1
• 210000001539 phagocyte Anatomy 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• 229940072689 plaquenil Drugs 0.000 description 1
• 229940063179 platinol Drugs 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 201000006292 polyarteritis nodosa Diseases 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 230000005195 poor health Effects 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 238000010149 post-hoc-test Methods 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 238000011533 pre-incubation Methods 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000001902 propagating effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 230000005892 protein maturation Effects 0.000 description 1
• 238000003906 pulsed field gel electrophoresis Methods 0.000 description 1
• 230000006824 pyrimidine synthesis Effects 0.000 description 1
• 239000002287 radioligand Substances 0.000 description 1
• 239000012217 radiopharmaceutical Substances 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 239000003087 receptor blocking agent Substances 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 208000034213 recurrent susceptibility to 1 pregnancy loss Diseases 0.000 description 1
• 229940087462 relafen Drugs 0.000 description 1
• 229940116176 remicade Drugs 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 239000003340 retarding agent Substances 0.000 description 1
• 201000006845 reticulosarcoma Diseases 0.000 description 1
• 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 229940061969 rheumatrex Drugs 0.000 description 1
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
• 150000003873 salicylate salts Chemical class 0.000 description 1
• 229940063122 sandimmune Drugs 0.000 description 1
• 210000003752 saphenous vein Anatomy 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 238000009738 saturating Methods 0.000 description 1
• 230000037390 scarring Effects 0.000 description 1
• 238000013391 scatchard analysis Methods 0.000 description 1
• 208000010157 sclerosing cholangitis Diseases 0.000 description 1
• 208000016997 secondary vasculitis Diseases 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 239000013049 sediment Substances 0.000 description 1
• 238000004062 sedimentation Methods 0.000 description 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 239000002356 single layer Substances 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
• 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
• 229940100996 sodium bisulfate Drugs 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 235000010265 sodium sulphite Nutrition 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 230000001148 spastic effect Effects 0.000 description 1
• 150000003408 sphingolipids Chemical class 0.000 description 1
• 238000003153 stable transfection Methods 0.000 description 1
• 238000007447 staining method Methods 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 238000012414 sterilization procedure Methods 0.000 description 1
• 230000003637 steroidlike Effects 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
• 229960001940 sulfasalazine Drugs 0.000 description 1
• MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 108010033090 surfactant protein A receptor Proteins 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 229960002372 tetracaine Drugs 0.000 description 1
• GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 229960001196 thiotepa Drugs 0.000 description 1
• 230000003582 thrombocytopenic effect Effects 0.000 description 1
• 208000008732 thymoma Diseases 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
• 229960000984 tocofersolan Drugs 0.000 description 1
• 238000003325 tomography Methods 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 229960005267 tositumomab Drugs 0.000 description 1
• 230000002110 toxicologic effect Effects 0.000 description 1
• 231100000759 toxicological effect Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 238000012549 training Methods 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 238000003146 transient transfection Methods 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 230000005740 tumor formation Effects 0.000 description 1
• 238000007492 two-way ANOVA Methods 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 238000002562 urinalysis Methods 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 238000009777 vacuum freeze-drying Methods 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 229940063674 voltaren Drugs 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
• 229960001600 xylazine Drugs 0.000 description 1
• 239000002076 α-tocopherol Substances 0.000 description 1
• 235000004835 α-tocopherol Nutrition 0.000 description 1